We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Werfen Unveils Next Generation Hemostasis Testing Systems

By LabMedica International staff writers
Posted on 30 Jul 2025

Werfen (Barcelona, Spain) is unveiling the next generation of market-leading ACL TOP hemostasis testing systems at the ADLM Annual Meeting 2025, reinforcing the company’s commitment to innovation in specialized diagnostics. More...

Werfen also has announced the expansion of its award-winning Gem Premier 7000 with iQM3 to Europe, following its strong clinical adoption in North America.

Werfen had recently announced the commercialization of ACL TOP Family 70 Series hemostasis testing systems in North America, following 510(k) clearance by the US Food and Drug Administration and licensure by Health Canada. Building upon the company’s established legacy of quality and innovation in hemostasis testing, the ACL TOP Family 70 series hemostasis testing systems optimize workflow with a powerful combination of quality and efficiency, and connectivity across an entire laboratory network. To streamline and optimize workflow, ACL TOP Family 70 Series systems offer centralized QC and automated performance verification management. When connected to HemoHub Intelligent Data Manager, synergistic integration allows uniform application of a laboratory’s Quality Management System across multiple instruments and sites, from one centralized location; transcription errors are eliminated, and report generation and storage are automated. Performance verification studies that previously involved several manual processes are reduced to two automated steps, saving significant staff time, improving quality, and reducing costs.

At ADLM 2025, Werfen has announced the expanded commercialization for the GEM Premier 7000 with iQM3, following its early success in North America. Building on strong clinical adoption and recognition in the United States, the system is now available in Europe. The GEM Premier 7000 is the first blood gas testing system to integrate hemolysis detection at the point of care, addressing the most common preanalytical error in blood gas testing. The system earned five prestigious industry awards, including the 2025 Edison Award and Premier Inc. Supplier Innovation Award, for its groundbreaking integration of hemolysis detection at the point of care. These honors highlight its innovation, quality, and positive impact on clinical workflows and patient care.

Related Links:
Werfen


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Automatic CLIA Analyzer
Shine i6000
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.